Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Becton, Dickinson and Company

https://www.bd.com/en-us

Latest From Becton, Dickinson and Company

Chinese Drug Makers Trim, Boost Pipelines In New R&D Drive

The ranks of B7-H3-targeting antibody-drug conjugates under development in China have seen their first dropout, although elsewhere there are two FGFR2b-directed ADCs with first-in-class potential on the horizon. Meanwhile, there have been other discontinuations of KRAS G12C inhibitors and anti-BCMA CAR-T cell therapies in the country, while new players have surfaced in the areas of mRNA cancer vaccines and amyloid-beta-targeting antibodies for Alzheimer’s disease.

China Research & Development

ViiV Healthcare And Medicines Patent Pool Celebrate 10-Year HIV Collaboration

On the heels of a decade-long partnership with ViiV Healthcare that has helped 24 million people with HIV, the Medicines Patent Pool introduces a new version of its patent database for essential medicines and COVID-19 vaccines.

Market Access Emerging Markets

Rx Advertising: Interchangeability Doesn’t Mean Clinical Superiority To Other Biosimilars, FDA Says

Updated draft guidance on promotion of biologic reference products, biosimilars and interchangeable biosimilars offers another indication of the US’s push to do away with the interchangeability designation.

Biosimilars Advertising, Marketing & Sales

Finance Watch: Venture Rounds Trend Toward The High End

Private Company Edition: First quarter data again confirm fewer but larger VC rounds in Q1. Big Q2 rounds include a $132.5m series C round for Endeavor Biomedicines, a $103m series A round for Reunion Neuroscience and Enlaza’s $100m series A.

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Medical Devices
    • Diagnostic Equipment & Supplies
    • Implantable Devices
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • BD
    • BD Medical
    • Bridger Biomed, Inc.
    • Caesarea Medical Electronics
    • CareFusion
    • Carmel Pharma, Inc.
    • Carmel Pharma, AB
    • Cellular Research, Inc.
    • C.R. Bard, Inc.
    • CRISI Medical Systems
    • Davol, Inc.
    • Embo Medical Limited
    • FlowCardia, Inc.
    • GenCell Biosystems, Ltd.
    • GeneOhm Sciences
    • Liberator Medical, Inc.
    • Lutonix, Inc.
    • Medafor, Inc.
    • Medicon, Inc.
    • Neomend, Inc.
    • Sirigen Group Limited
    • TriPath Imaging
    • TVA Medical, Inc.
    • Rochester Medical, Inc.
    • Safety Syringes Inc.
    • Vascular Pathways, Inc.
    • Venclose, Inc.
UsernamePublicRestriction

Register